Neurodegenerative Disorders Market Likely to Surpass ~USD 70 Billion by 2035

• 1. Research Methodology and Assumptions
  • 1.1. Definitions
  • 1.2. Research Design and Approach
  • 1.3. Data Collection Methods
  • 1.4. Base Estimates and Calculations
  • 1.5. Forecasting Models
    • 1.5.1. Key Forecast Factors & Impact Analysis
  • 1.6. Secondary Research
    • 1.6.1. Open Sources
    • 1.6.2. Paid Databases
    • 1.6.3. Associations
  • 1.7. Primary Research
    • 1.7.1. Primary Sources
    • 1.7.2. Primary Interviews with Stakeholders across Ecosystem
• 2. Executive Summary
  • 2.1. Global Neurogenerative Disorders Market Outlook
    • 2.1.1. Neurogenerative Disorders Market Size (Value - US$ Bn), and Forecasts, 2021-2035
    • 2.1.2. Compounded Annual Growth Rate Analysis
    • 2.1.3. Growth Opportunity Analysis
    • 2.1.4. Segmental Share Analysis
    • 2.1.5. Geographical Share Analysis
  • 2.2. Market Analysis and Facts
  • 2.3. Supply-Demand Analysis
  • 2.4. Competitive Benchmarking
  • 2.5. Go-to- Market Strategy
    • 2.5.1. Customer/ End-use Industry Assessment
    • 2.5.2. Growth Opportunity Data, 2025-2035
      • 2.5.2.1. Regional Data
      • 2.5.2.2. Country Data
      • 2.5.2.3. Segmental Data
    • 2.5.3. Identification of Potential Market Spaces
    • 2.5.4. GAP Analysis
    • 2.5.5. Potential Attractive Price Points
    • 2.5.6. Prevailing Market Risks & Challenges
    • 2.5.7. Preferred Sales & Marketing Strategies
    • 2.5.8. Key Recommendations and Analysis
    • 2.5.9. A Way Forward
• 3. Industry Data and Premium Insights
  • 3.1. Global Neurogenerative Disorders Industry Overview, 2025
    • 3.1.1. Healthcare & Pharmaceutical Industry Ecosystem Analysis
    • 3.1.2. Key Trends for Healthcare & Pharmaceutical Industry
    • 3.1.3. Regional Distribution for Healthcare & Pharmaceutical Industry
  • 3.2. Supplier Customer Data
  • 3.3. Technology Roadmap and Developments
  • 3.4. Trade Analysis
    • 3.4.1. Import & Export Analysis, 2025
    • 3.4.2. Top Importing Countries
    • 3.4.3. Top Exporting Countries
  • 3.5. Trump Tariff Impact Analysis
    • 3.5.1. Manufacturer
      • 3.5.1.1. Based on the component & Raw material
    • 3.5.2. Supply Chain
    • 3.5.3. End Consumer
  • 3.6. Raw Material Analysis
• 4. Market Overview
  • 4.1. Market Dynamics
    • 4.1.1. Drivers
      • 4.1.1.1. Aging population & rising disease prevalence
      • 4.1.1.2. Advances in gene/cell therapies and biomarkers
      • 4.1.1.3. Rising R&D investment and regulatory incentives
    • 4.1.2. Restraints
      • 4.1.2.1. Complex biology (blood–brain barrier) and long clinical timelines
      • 4.1.2.2. High development costs and uncertain reimbursement
  • 4.2. Key Trend Analysis
  • 4.3. Regulatory Framework
    • 4.3.1. Key Regulations, Norms, and Subsidies, by Key Countries
    • 4.3.2. Tariffs and Standards
    • 4.3.3. Impact Analysis of Regulations on the Market
  • 4.4. Ecosystem Analysis
  • 4.5. Porter’s Five Forces Analysis
  • 4.6. PESTEL Analysis
  • 4.7. Global Neurogenerative Disorders Market Demand
    • 4.7.1. Historical Market Size - in Value (US$ Bn), 2020-2024
    • 4.7.2. Current and Future Market Size - in Value (US$ Bn), 2026–2035
      • 4.7.2.1. Y-o-Y Growth Trends
      • 4.7.2.2. Absolute $ Opportunity Assessment
• 5. Competition Landscape
  • 5.1. Competition structure
    • 5.1.1. Fragmented v/s consolidated
  • 5.2. Company Share Analysis, 2025
    • 5.2.1. Global Company Market Share
    • 5.2.2. By Region
      • 5.2.2.1. North America
      • 5.2.2.2. Europe
      • 5.2.2.3. Asia Pacific
      • 5.2.2.4. Middle East
      • 5.2.2.5. Africa
      • 5.2.2.6. South America
  • 5.3. Product Comparison Matrix
    • 5.3.1. Specifications
    • 5.3.2. Market Positioning
    • 5.3.3. Pricing
• 6. Global Neurogenerative Disorders Market Analysis, By Disease Type
  • 6.1. Key Segment Analysis
  • 6.2. Neurogenerative Disorders Market Size (Value - US$ Bn), Analysis, and Forecasts, By Disease Type, 2021-2035
    • 6.2.1. Alzheimer's Disease
    • 6.2.2. Parkinson's Disease
    • 6.2.3. Huntington's Disease
    • 6.2.4. Amyotrophic Lateral Sclerosis (ALS)
    • 6.2.5. Multiple Sclerosis (MS)
    • 6.2.6. Others
• 7. Global Neurogenerative Disorders Market Analysis, By Drug Class
  • 7.1. Key Segment Analysis
  • 7.2. Neurogenerative Disorders Market Size (Value - US$ Bn), Analysis, and Forecasts, By Drug Class, 2021-2035
    • 7.2.1. Cholinesterase Inhibitors
    • 7.2.2. NMDA Receptor Antagonists
    • 7.2.3. Dopamine Agonists
    • 7.2.4. MAO-B Inhibitors
    • 7.2.5. COMT Inhibitors
    • 7.2.6. Immunomodulators
    • 7.2.7. Immunosuppressants
    • 7.2.8. Others
• 8. Global Neurogenerative Disorders Market Analysis and Forecasts,By Route of Administration
  • 8.1. Key Findings
  • 8.2. Neurogenerative Disorders Market Size (Value - US$ Mn), Analysis, and Forecasts, By Route of Administration, 2021-2035
    • 8.2.1. Oral
    • 8.2.2. Injectable
      • 8.2.2.1. Subcutaneous
      • 8.2.2.2. Intramuscular
      • 8.2.2.3. Intravenous
      • 8.2.2.4. Others
    • 8.2.3. Transdermal Patches
    • 8.2.4. Inhalation
• 9. Global Neurogenerative Disorders Market Analysis and Forecasts, By Mechanism of Action
  • 9.1. Key Findings
  • 9.2. Neurogenerative Disorders Market Size (Vo Value - US$ Mn), Analysis, and Forecasts, By Mechanism of Action, 2021-2035
    • 9.2.1. Symptomatic Treatment
    • 9.2.2. Disease-Modifying Treatment
    • 9.2.3. Neuroprotective Agents
    • 9.2.4. Anti-inflammatory Agents
    • 9.2.5. Gene Therapy
    • 9.2.6. Cell Therapy
    • 9.2.7. Others
• 10. Global Neurogenerative Disorders Market Analysis and Forecasts, By Stage of Disease
  • 10.1. Key Findings
  • 10.2. Neurogenerative Disorders Market Size (Value - US$ Mn), Analysis, and Forecasts, By Stage of Disease, 2021-2035
    • 10.2.1. Early Stage/Mild
    • 10.2.2. Moderate Stage
    • 10.2.3. Advanced/Severe Stage
    • 10.2.4. Preclinical/Prodromal
• 11. Global Neurogenerative Disorders Market Analysis and Forecasts, By Patient Demographics
  • 11.1. Key Findings
  • 11.2. Neurogenerative Disorders Market Size (Value - US$ Mn), Analysis, and Forecasts, By Patient Demographics, 2021-2035
    • 11.2.1. Pediatric
    • 11.2.2. Adult
    • 11.2.3. Geriatric
• 12. Global Neurogenerative Disorders Market Analysis and Forecasts, By End-users
  • 12.1. Key Findings
  • 12.2. Neurogenerative Disorders Market Size (Value - US$ Mn), Analysis, and Forecasts, By End-users, 2021-2035
    • 12.2.1. Hospitals & Clinics
      • 12.2.1.1. Diagnosis & Screening
      • 12.2.1.2. Disease Management
      • 12.2.1.3. Symptomatic Treatment
      • 12.2.1.4. Rehabilitation Services
      • 12.2.1.5. Emergency Care
      • 12.2.1.6. Inpatient Treatment
      • 12.2.1.7. Others
    • 12.2.2. Research & Academic Institutions
      • 12.2.2.1. Clinical Trials
      • 12.2.2.2. Drug Discovery & Development
      • 12.2.2.3. Biomarker Research
      • 12.2.2.4. Genetic Studies
      • 12.2.2.5. Epidemiological Studies
      • 12.2.2.6. Others
    • 12.2.3. Pharmaceutical & Biotechnology Companies
      • 12.2.3.1. Drug Manufacturing
      • 12.2.3.2. Biologics Production
      • 12.2.3.3. Gene Therapy Development
      • 12.2.3.4. Vaccine Development
      • 12.2.3.5. Clinical Development
      • 12.2.3.6. Others
    • 12.2.4. Diagnostic Laboratories
      • 12.2.4.1. Biomarker Testing
      • 12.2.4.2. Genetic Screening
      • 12.2.4.3. CSF Analysis
      • 12.2.4.4. Neuroimaging Services
      • 12.2.4.5. Pathology Services
      • 12.2.4.6. Others
    • 12.2.5. Home Healthcare Providers
      • 12.2.5.1. Long-term Care Management
      • 12.2.5.2. Medication Administration
      • 12.2.5.3. Patient Monitoring
      • 12.2.5.4. Rehabilitation Support
      • 12.2.5.5. Palliative Care
      • 12.2.5.6. Others
    • 12.2.6. Specialty Clinics
      • 12.2.6.1. Movement Disorder Clinics
      • 12.2.6.2. Memory Clinics
      • 12.2.6.3. ALS Clinics
      • 12.2.6.4. MS Centers
      • 12.2.6.5. Cognitive Assessment Centers
      • 12.2.6.6. Others
    • 12.2.7. Other End-users
• 13. Global Neurogenerative Disorders Market Analysis and Forecasts, by Region
  • 13.1. Key Findings
  • 13.2. Neurogenerative Disorders Market Size (Value - US$ Mn), Analysis, and Forecasts, by Region, 2021-2035
    • 13.2.1. North America
    • 13.2.2. Europe
    • 13.2.3. Asia Pacific
    • 13.2.4. Middle East
    • 13.2.5. Africa
    • 13.2.6. South America
• 14. North America Neurogenerative Disorders Market Analysis
  • 14.1. Key Segment Analysis
  • 14.2. Regional Snapshot
  • 14.3. North America Neurogenerative Disorders Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
    • 14.3.1. Disease Type
    • 14.3.2. Drug Class
    • 14.3.3. Route of Administration
    • 14.3.4. Mechanism of Action
    • 14.3.5. Stage of Disease
    • 14.3.6. Patient Demographics
    • 14.3.7. End-Users
    • 14.3.8. Country
      • 14.3.8.1. USA
      • 14.3.8.2. Canada
      • 14.3.8.3. Mexico
  • 14.4. USA Neurogenerative Disorders Market
    • 14.4.1. Country Segmental Analysis
    • 14.4.2. Disease Type
    • 14.4.3. Drug Class
    • 14.4.4. Route of Administration
    • 14.4.5. Mechanism of Action
    • 14.4.6. Stage of Disease
    • 14.4.7. Patient Demographics
    • 14.4.8. End-Users
  • 14.5. Canada Neurogenerative Disorders Market
    • 14.5.1. Country Segmental Analysis
    • 14.5.2. Disease Type
    • 14.5.3. Drug Class
    • 14.5.4. Route of Administration
    • 14.5.5. Mechanism of Action
    • 14.5.6. Stage of Disease
    • 14.5.7. Patient Demographics
    • 14.5.8. End-Users
  • 14.6. Mexico Neurogenerative Disorders Market
    • 14.6.1. Country Segmental Analysis
    • 14.6.2. Disease Type
    • 14.6.3. Drug Class
    • 14.6.4. Route of Administration
    • 14.6.5. Mechanism of Action
    • 14.6.6. Stage of Disease
    • 14.6.7. Patient Demographics
    • 14.6.8. End-Users
• 15. Europe Neurogenerative Disorders Market Analysis
  • 15.1. Key Segment Analysis
  • 15.2. Regional Snapshot
  • 15.3. Europe Neurogenerative Disorders Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
    • 15.3.1. Disease Type
    • 15.3.2. Drug Class
    • 15.3.3. Route of Administration
    • 15.3.4. Mechanism of Action
    • 15.3.5. Stage of Disease
    • 15.3.6. Patient Demographics
    • 15.3.7. End-Users
    • 15.3.8. Country
      • 15.3.8.1. Germany
      • 15.3.8.2. United Kingdom
      • 15.3.8.3. France
      • 15.3.8.4. Italy
      • 15.3.8.5. Spain
      • 15.3.8.6. Netherlands
      • 15.3.8.7. Nordic Countries
      • 15.3.8.8. Poland
      • 15.3.8.9. Russia & CIS
      • 15.3.8.10. Rest of Europe
  • 15.4. Germany Neurogenerative Disorders Market
    • 15.4.1. Country Segmental Analysis
    • 15.4.2. Disease Type
    • 15.4.3. Drug Class
    • 15.4.4. Route of Administration
    • 15.4.5. Mechanism of Action
    • 15.4.6. Stage of Disease
    • 15.4.7. Patient Demographics
    • 15.4.8. End-Users
  • 15.5. United Kingdom Neurogenerative Disorders Market
    • 15.5.1. Country Segmental Analysis
    • 15.5.2. Disease Type
    • 15.5.3. Drug Class
    • 15.5.4. Route of Administration
    • 15.5.5. Mechanism of Action
    • 15.5.6. Stage of Disease
    • 15.5.7. Patient Demographics
    • 15.5.8. End-Users
  • 15.6. France Neurogenerative Disorders Market
    • 15.6.1. Country Segmental Analysis
    • 15.6.2. Disease Type
    • 15.6.3. Drug Class
    • 15.6.4. Route of Administration
    • 15.6.5. Mechanism of Action
    • 15.6.6. Stage of Disease
    • 15.6.7. Patient Demographics
    • 15.6.8. End-Users
  • 15.7. Italy Neurogenerative Disorders Market
    • 15.7.1. Country Segmental Analysis
    • 15.7.2. Disease Type
    • 15.7.3. Drug Class
    • 15.7.4. Route of Administration
    • 15.7.5. Mechanism of Action
    • 15.7.6. Stage of Disease
    • 15.7.7. Patient Demographics
    • 15.7.8. End-Users
  • 15.8. Spain Neurogenerative Disorders Market
    • 15.8.1. Country Segmental Analysis
    • 15.8.2. Disease Type
    • 15.8.3. Drug Class
    • 15.8.4. Route of Administration
    • 15.8.5. Mechanism of Action
    • 15.8.6. Stage of Disease
    • 15.8.7. Patient Demographics
    • 15.8.8. End-Users
  • 15.9. Netherlands Neurogenerative Disorders Market
    • 15.9.1. Country Segmental Analysis
    • 15.9.2. Disease Type
    • 15.9.3. Drug Class
    • 15.9.4. Route of Administration
    • 15.9.5. Mechanism of Action
    • 15.9.6. Stage of Disease
    • 15.9.7. Patient Demographics
    • 15.9.8. End-Users
  • 15.10. Nordic Countries Neurogenerative Disorders Market
    • 15.10.1. Country Segmental Analysis
    • 15.10.2. Disease Type
    • 15.10.3. Drug Class
    • 15.10.4. Route of Administration
    • 15.10.5. Mechanism of Action
    • 15.10.6. Stage of Disease
    • 15.10.7. Patient Demographics
    • 15.10.8. End-Users
  • 15.11. Poland Neurogenerative Disorders Market
    • 15.11.1. Country Segmental Analysis
    • 15.11.2. Disease Type
    • 15.11.3. Drug Class
    • 15.11.4. Route of Administration
    • 15.11.5. Mechanism of Action
    • 15.11.6. Stage of Disease
    • 15.11.7. Patient Demographics
    • 15.11.8. End-Users
  • 15.12. Russia & CIS Neurogenerative Disorders Market
    • 15.12.1. Country Segmental Analysis
    • 15.12.2. Disease Type
    • 15.12.3. Drug Class
    • 15.12.4. Route of Administration
    • 15.12.5. Mechanism of Action
    • 15.12.6. Stage of Disease
    • 15.12.7. Patient Demographics
    • 15.12.8. End-Users
  • 15.13. Rest of Europe Neurogenerative Disorders Market
    • 15.13.1. Country Segmental Analysis
    • 15.13.2. Disease Type
    • 15.13.3. Drug Class
    • 15.13.4. Route of Administration
    • 15.13.5. Mechanism of Action
    • 15.13.6. Stage of Disease
    • 15.13.7. Patient Demographics
    • 15.13.8. End-Users
• 16. Asia Pacific Neurogenerative Disorders Market Analysis
  • 16.1. Key Segment Analysis
  • 16.2. Regional Snapshot
  • 16.3. Asia Pacific Neurogenerative Disorders Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
    • 16.3.1. Disease Type
    • 16.3.2. Drug Class
    • 16.3.3. Route of Administration
    • 16.3.4. Mechanism of Action
    • 16.3.5. Stage of Disease
    • 16.3.6. Patient Demographics
    • 16.3.7. End-Users
    • 16.3.8. Country
      • 16.3.8.1. China
      • 16.3.8.2. India
      • 16.3.8.3. Japan
      • 16.3.8.4. South Korea
      • 16.3.8.5. Australia and New Zealand
      • 16.3.8.6. Indonesia
      • 16.3.8.7. Malaysia
      • 16.3.8.8. Thailand
      • 16.3.8.9. Vietnam
      • 16.3.8.10. Rest of Asia Pacific
  • 16.4. China Neurogenerative Disorders Market
    • 16.4.1. Country Segmental Analysis
    • 16.4.2. Disease Type
    • 16.4.3. Drug Class
    • 16.4.4. Route of Administration
    • 16.4.5. Mechanism of Action
    • 16.4.6. Stage of Disease
    • 16.4.7. Patient Demographics
    • 16.4.8. End-Users
  • 16.5. India Neurogenerative Disorders Market
    • 16.5.1. Country Segmental Analysis
    • 16.5.2. Disease Type
    • 16.5.3. Drug Class
    • 16.5.4. Route of Administration
    • 16.5.5. Mechanism of Action
    • 16.5.6. Stage of Disease
    • 16.5.7. Patient Demographics
    • 16.5.8. End-Users
  • 16.6. Japan Neurogenerative Disorders Market
    • 16.6.1. Country Segmental Analysis
    • 16.6.2. Disease Type
    • 16.6.3. Drug Class
    • 16.6.4. Route of Administration
    • 16.6.5. Mechanism of Action
    • 16.6.6. Stage of Disease
    • 16.6.7. Patient Demographics
    • 16.6.8. End-Users
  • 16.7. South Korea Neurogenerative Disorders Market
    • 16.7.1. Country Segmental Analysis
    • 16.7.2. Disease Type
    • 16.7.3. Drug Class
    • 16.7.4. Route of Administration
    • 16.7.5. Mechanism of Action
    • 16.7.6. Stage of Disease
    • 16.7.7. Patient Demographics
    • 16.7.8. End-Users
  • 16.8. Australia and New Zealand Neurogenerative Disorders Market
    • 16.8.1. Country Segmental Analysis
    • 16.8.2. Disease Type
    • 16.8.3. Drug Class
    • 16.8.4. Route of Administration
    • 16.8.5. Mechanism of Action
    • 16.8.6. Stage of Disease
    • 16.8.7. Patient Demographics
    • 16.8.8. End-Users
  • 16.9. Indonesia Neurogenerative Disorders Market
    • 16.9.1. Country Segmental Analysis
    • 16.9.2. Disease Type
    • 16.9.3. Drug Class
    • 16.9.4. Route of Administration
    • 16.9.5. Mechanism of Action
    • 16.9.6. Stage of Disease
    • 16.9.7. Patient Demographics
    • 16.9.8. End-Users
  • 16.10. Malaysia Neurogenerative Disorders Market
    • 16.10.1. Country Segmental Analysis
    • 16.10.2. Disease Type
    • 16.10.3. Drug Class
    • 16.10.4. Route of Administration
    • 16.10.5. Mechanism of Action
    • 16.10.6. Stage of Disease
    • 16.10.7. Patient Demographics
    • 16.10.8. End-Users
  • 16.11. Thailand Neurogenerative Disorders Market
    • 16.11.1. Country Segmental Analysis
    • 16.11.2. Disease Type
    • 16.11.3. Drug Class
    • 16.11.4. Route of Administration
    • 16.11.5. Mechanism of Action
    • 16.11.6. Stage of Disease
    • 16.11.7. Patient Demographics
    • 16.11.8. End-Users
  • 16.12. Vietnam Neurogenerative Disorders Market
    • 16.12.1. Country Segmental Analysis
    • 16.12.2. Disease Type
    • 16.12.3. Drug Class
    • 16.12.4. Route of Administration
    • 16.12.5. Mechanism of Action
    • 16.12.6. Stage of Disease
    • 16.12.7. Patient Demographics
    • 16.12.8. End-Users
  • 16.13. Rest of Asia Pacific Neurogenerative Disorders Market
    • 16.13.1. Country Segmental Analysis
    • 16.13.2. Disease Type
    • 16.13.3. Drug Class
    • 16.13.4. Route of Administration
    • 16.13.5. Mechanism of Action
    • 16.13.6. Stage of Disease
    • 16.13.7. Patient Demographics
    • 16.13.8. End-Users
• 17. Middle East Neurogenerative Disorders Market Analysis
  • 17.1. Key Segment Analysis
  • 17.2. Regional Snapshot
  • 17.3. Middle East Neurogenerative Disorders Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
    • 17.3.1. Disease Type
    • 17.3.2. Drug Class
    • 17.3.3. Route of Administration
    • 17.3.4. Mechanism of Action
    • 17.3.5. Stage of Disease
    • 17.3.6. Patient Demographics
    • 17.3.7. End-Users
    • 17.3.8. Country
      • 17.3.8.1. Turkey
      • 17.3.8.2. UAE
      • 17.3.8.3. Saudi Arabia
      • 17.3.8.4. Israel
      • 17.3.8.5. Rest of Middle East
  • 17.4. Turkey Neurogenerative Disorders Market
    • 17.4.1. Country Segmental Analysis
    • 17.4.2. Disease Type
    • 17.4.3. Drug Class
    • 17.4.4. Route of Administration
    • 17.4.5. Mechanism of Action
    • 17.4.6. Stage of Disease
    • 17.4.7. Patient Demographics
    • 17.4.8. End-Users
  • 17.5. UAE Neurogenerative Disorders Market
    • 17.5.1. Country Segmental Analysis
    • 17.5.2. Disease Type
    • 17.5.3. Drug Class
    • 17.5.4. Route of Administration
    • 17.5.5. Mechanism of Action
    • 17.5.6. Stage of Disease
    • 17.5.7. Patient Demographics
    • 17.5.8. End-Users
  • 17.6. Saudi Arabia Neurogenerative Disorders Market
    • 17.6.1. Country Segmental Analysis
    • 17.6.2. Disease Type
    • 17.6.3. Drug Class
    • 17.6.4. Route of Administration
    • 17.6.5. Mechanism of Action
    • 17.6.6. Stage of Disease
    • 17.6.7. Patient Demographics
    • 17.6.8. End-Users
  • 17.7. Israel Neurogenerative Disorders Market
    • 17.7.1. Country Segmental Analysis
    • 17.7.2. Disease Type
    • 17.7.3. Drug Class
    • 17.7.4. Route of Administration
    • 17.7.5. Mechanism of Action
    • 17.7.6. Stage of Disease
    • 17.7.7. Patient Demographics
    • 17.7.8. End-Users
  • 17.8. Rest of Middle East Neurogenerative Disorders Market
    • 17.8.1. Country Segmental Analysis
    • 17.8.2. Disease Type
    • 17.8.3. Drug Class
    • 17.8.4. Route of Administration
    • 17.8.5. Mechanism of Action
    • 17.8.6. Stage of Disease
    • 17.8.7. Patient Demographics
    • 17.8.8. End-Users
• 18. Africa Neurogenerative Disorders Market Analysis
  • 18.1. Key Segment Analysis
  • 18.2. Regional Snapshot
  • 18.3. Africa Neurogenerative Disorders Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
    • 18.3.1. Disease Type
    • 18.3.2. Drug Class
    • 18.3.3. Route of Administration
    • 18.3.4. Mechanism of Action
    • 18.3.5. Stage of Disease
    • 18.3.6. Patient Demographics
    • 18.3.7. End-Users
    • 18.3.8. Country
      • 18.3.8.1. South Africa
      • 18.3.8.2. Egypt
      • 18.3.8.3. Nigeria
      • 18.3.8.4. Algeria
      • 18.3.8.5. Rest of Africa
  • 18.4. South Africa Neurogenerative Disorders Market
    • 18.4.1. Country Segmental Analysis
    • 18.4.2. Disease Type
    • 18.4.3. Drug Class
    • 18.4.4. Route of Administration
    • 18.4.5. Mechanism of Action
    • 18.4.6. Stage of Disease
    • 18.4.7. Patient Demographics
    • 18.4.8. End-Users
  • 18.5. Egypt Neurogenerative Disorders Market
    • 18.5.1. Country Segmental Analysis
    • 18.5.2. Disease Type
    • 18.5.3. Drug Class
    • 18.5.4. Route of Administration
    • 18.5.5. Mechanism of Action
    • 18.5.6. Stage of Disease
    • 18.5.7. Patient Demographics
    • 18.5.8. End-Users
  • 18.6. Nigeria Neurogenerative Disorders Market
    • 18.6.1. Country Segmental Analysis
    • 18.6.2. Disease Type
    • 18.6.3. Drug Class
    • 18.6.4. Route of Administration
    • 18.6.5. Mechanism of Action
    • 18.6.6. Stage of Disease
    • 18.6.7. Patient Demographics
    • 18.6.8. End-Users
  • 18.7. Algeria Neurogenerative Disorders Market
    • 18.7.1. Country Segmental Analysis
    • 18.7.2. Disease Type
    • 18.7.3. Drug Class
    • 18.7.4. Route of Administration
    • 18.7.5. Mechanism of Action
    • 18.7.6. Stage of Disease
    • 18.7.7. Patient Demographics
    • 18.7.8. End-Users
  • 18.8. Rest of Africa Neurogenerative Disorders Market
    • 18.8.1. Country Segmental Analysis
    • 18.8.2. Disease Type
    • 18.8.3. Drug Class
    • 18.8.4. Route of Administration
    • 18.8.5. Mechanism of Action
    • 18.8.6. Stage of Disease
    • 18.8.7. Patient Demographics
    • 18.8.8. End-Users
• 19. South America Neurogenerative Disorders Market Analysis
  • 19.1. Key Segment Analysis
  • 19.2. Regional Snapshot
  • 19.3. South America Neurogenerative Disorders Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
    • 19.3.1. Disease Type
    • 19.3.2. Drug Class
    • 19.3.3. Route of Administration
    • 19.3.4. Mechanism of Action
    • 19.3.5. Stage of Disease
    • 19.3.6. Patient Demographics
    • 19.3.7. End-Users
    • 19.3.8. Country
      • 19.3.8.1. Brazil
      • 19.3.8.2. Argentina
      • 19.3.8.3. Rest of South America
  • 19.4. Brazil Neurogenerative Disorders Market
    • 19.4.1. Country Segmental Analysis
    • 19.4.2. Disease Type
    • 19.4.3. Drug Class
    • 19.4.4. Route of Administration
    • 19.4.5. Mechanism of Action
    • 19.4.6. Stage of Disease
    • 19.4.7. Patient Demographics
    • 19.4.8. End-Users
  • 19.5. Argentina Neurogenerative Disorders Market
    • 19.5.1. Country Segmental Analysis
    • 19.5.2. Disease Type
    • 19.5.3. Drug Class
    • 19.5.4. Route of Administration
    • 19.5.5. Mechanism of Action
    • 19.5.6. Stage of Disease
    • 19.5.7. Patient Demographics
    • 19.5.8. End-Users
  • 19.6. Rest of South America Neurogenerative Disorders Market
    • 19.6.1. Country Segmental Analysis
    • 19.6.2. Disease Type
    • 19.6.3. Drug Class
    • 19.6.4. Route of Administration
    • 19.6.5. Mechanism of Action
    • 19.6.6. Stage of Disease
    • 19.6.7. Patient Demographics
    • 19.6.8. End-Users
• 20. Key Players/ Company Profile
  • 20.1. AbbVie Inc.
    • 20.1.1. Company Details/ Overview
    • 20.1.2. Company Financials
    • 20.1.3. Key Customers and Competitors
    • 20.1.4. Business/ Industry Portfolio
    • 20.1.5. Product Portfolio/ Specification Details
    • 20.1.6. Pricing Data
    • 20.1.7. Strategic Overview
    • 20.1.8. Recent Developments
  • 20.2. Acorda Therapeutics, Inc.
  • 20.3. Amneal Pharmaceuticals LLC
  • 20.4. AstraZeneca plc
  • 20.5. Biogen Inc.
  • 20.6. Boehringer Ingelheim International GmbH
  • 20.7. Bristol-Myers Squibb Company
  • 20.8. Eisai Co., Ltd.
  • 20.9. Eli Lilly and Company
  • 20.10. GlaxoSmithKline plc
  • 20.11. Johnson & Johnson
  • 20.12. Lundbeck A/S
  • 20.13. Merck & Co., Inc.
  • 20.14. Novartis AG
  • 20.15. Orion Corporation
  • 20.16. Pfizer Inc.
  • 20.17. Roche Holding AG
  • 20.18. Sanofi S.A.
  • 20.19. Teva Pharmaceutical Industries Ltd.
  • 20.20. UCB S.A.
  • 20.21. Other Key Players

Note* - This is just tentative list of players. While providing the report, we will cover more number of players based on their revenue and share for each geography